# Dexcom Raises Annual Outlook and Authorizes $1 Billion Share Buyback

Revenue rose 11%, while GAAP net income declined despite improved operating profit.

By Will Langan | 24X7 News
Published: 2026-10-29T22:59:03.777Z
Updated: 2026-10-29T22:59:03.777Z
Section: Health
Format: News
Canonical: https://24x7news.us/articles/dexcom-third-quarter-results-october-29-2026

Dexcom raised its annual revenue outlook and announced a share-repurchase authorization of up to $1 billion on October 29.

The glucose-monitoring company now expects 2026 revenue of $5.20 billion to $5.25 billion, representing approximately 12%–13% growth. It also increased its adjusted operating-margin forecast to approximately 24%.

Third-quarter revenue rose 11% from a year earlier to $1.344 billion. U.S. revenue increased 14%, while international revenue grew 5%.

GAAP operating income reached $327.2 million, or 24.3% of revenue, compared with $242.5 million, or 20.1%, a year earlier.

GAAP net income moved in the opposite direction, declining to $275.1 million from $283.8 million. Diluted earnings increased to 72 cents per share from 70 cents.

Adjusted net income was $275 million, or 73 cents per diluted share. Those adjusted results exclude specified items included in GAAP figures.

Dexcom held $1.82 billion in cash, cash equivalents and marketable securities at September 30, with its revolving credit facility undrawn.

The annual outlook remains a forecast. The buyback authorization permits future purchases and does not establish that the full amount has been spent.

Sources:
Dexcom — October 29 Results via Business Wire: https://www.stocktitan.net/news/DXCM/dexcom-reports-third-quarter-2026-financial-1syfpa94iw1d.html

## Sources
- Dexcom — October 29 Results via Business Wire: https://www.stocktitan.net/news/DXCM/dexcom-reports-third-quarter-2026-financial-1syfpa94iw1d.html